Viruses,
Год журнала:
2023,
Номер
15(8), С. 1625 - 1625
Опубликована: Июль 26, 2023
It
is
known
that
SARS-CoV-2
infection
can
result
in
gastrointestinal
symptoms.
For
some,
these
symptoms
may
persist
beyond
acute
infection,
what
as
'post-COVID
syndrome'.
We
conducted
a
systematic
review
to
examine
the
prevalence
of
persistent
and
incidence
new
illnesses
following
infection.
searched
scientific
literature
using
MedLine,
SCOPUS,
Europe
PubMed
Central
medRxiv
from
December
2019
July
2023.
Two
reviewers
independently
identified
45
eligible
articles,
which
followed
participants
for
various
outcomes
after
The
study
quality
was
assessed
Joanna
Briggs
Institute
Critical
Appraisal
Tools.
weighted
pooled
any
nature
duration
10.8%
compared
with
4.9%
healthy
controls.
seven
studies
at
low
risk
methodological
bias,
symptom
ranged
0.2%
24.1%,
median
follow-up
time
18
weeks.
also
higher
future
such
irritable
bowel
syndrome,
dyspepsia,
hepatic
biliary
disease,
liver
disease
autoimmune-mediated
inflammatory
coeliac
historically
SARS-CoV-2-exposed
individuals.
Our
has
shown
that,
limited
pool
mostly
low-quality
studies,
previous
exposure
be
associated
ongoing
development
functional
illness.
Furthermore,
we
show
need
high-quality
research
better
understand
association
illness,
particularly
population
enteric
infections
returns
pre-COVID-19-restriction
levels.
Infection and Chemotherapy,
Год журнала:
2024,
Номер
56(1), С. 122 - 122
Опубликована: Янв. 1, 2024
"Long
COVID"
is
a
term
used
to
describe
condition
when
the
symptoms
and
signs
associated
with
coronavirus
disease
2019
(COVID-19)
persist
for
more
than
three
months
among
patients
infected
COVID-19;
this
has
been
reported
globally
poses
serious
public
health
issue.
Long
COVID
can
manifest
in
various
forms,
highlighting
need
appropriate
evaluation
management
by
experts
from
fields.
However,
due
lack
of
clear
clinical
definitions,
knowledge
pathophysiology,
diagnostic
methods,
treatment
protocols,
it
necessary
develop
best
standard
guidelines
based
on
scientific
evidence
date.
We
developed
guideline
diagnosing
treating
long
analyzing
latest
research
data
collected
start
COVID-19
pandemic
until
June
2023,
along
consensus
expert
opinions.
This
provides
recommendations
diagnosis
that
be
applied
practice,
total
32
key
questions
related
COVID.
The
should
comprehensive,
including
medical
history,
physical
examination,
blood
tests,
imaging
studies,
functional
tests.
To
reduce
risk
developing
COVID,
vaccination
antiviral
during
acute
phase
are
recommended.
will
revised
there
reasonable
updates
availability
new
Pain,
Год журнала:
2021,
Номер
163(9), С. e989 - e996
Опубликована: Дек. 10, 2021
Abstract
This
study
investigated
the
prevalence
of
long-term
musculoskeletal
post-COVID
pain
and
their
risk
factors
in
a
large
cohort
COVID-19
survivors.
A
multicenter
including
patients
hospitalised
because
5
hospitals
Madrid
(Spain)
during
first
wave
pandemic
was
conducted.
Hospitalisation
clinical
data
were
collected
from
medical
records.
Patients
scheduled
for
telephone
interview
after
hospital
discharge
collecting
about
pain.
Anxiety/depressive
levels
sleep
quality
likewise
assessed.
From
2000
recruited,
total
1969
individuals
(46.4%
women,
age:
61
years,
SD:
16
years)
assessed
on
average
at
8.4
(SD:
1.5)
months
discharge.
At
time
study,
887
(45%
women)
reported
According
to
presence
previous
symptoms,
“de
novo”
(new-onset)
74.9%,
whereas
25.1%
experienced
an
increase
symptoms
(exacerbated
COVID-related
pain).
Female
sex
(odds
ratio
[OR]:
1.349,
95%
confidence
interval
[CI]:
1.059-1.720),
history
(OR
1.553,
CI
1.271-1.898),
myalgia
1.546,
1.155-2.070)
headache
(1.866,
1.349-2.580)
as
COVID-19–associated
onset
days
1.013,
1.004-1.022)
associated
with
In
conclusion,
is
present
45.1%
survivors
8
most
developing
de
novo
sex,
pain,
acute
phase,
International Journal of Clinical Practice,
Год журнала:
2021,
Номер
75(11)
Опубликована: Авг. 13, 2021
There
is
a
lack
of
an
overview
the
factors
associated
with
postacute
COVID-19
musculoskeletal
symptoms.
The
aims
this
study
were
as
follows:
1-
to
evaluate
most
frequent
admission
symptoms
and
frequency
in
patients;
2-
determine
related
symptoms.A
total
280
patients
(183
females,
97
males)
enrolled
divided
into
two
groups:
whose
initiated
or
aggravated
by
(n
=
240);
did
not
change
40).
variables
demographic
treatment
data,
on
admission,
symptoms,
laboratory
results
(complete
blood
count,
erythrocyte
sedimentation
rate,
C-reactive
protein,
ferritin
d-dimer),
chest
computed
tomography
findings
during
acute
COVID-19.Most
have
fatigue
(71.8%),
spine
pain
(70.7%)
myalgia
(60.7%).
common
region
was
back
(30.4%).
dyspnoea
30%,
cough
18.5%
10.7%.
Having
any
chronic
disease
(P
.031),
duration
hospital
stay
.016),
.018),
d-dimer
.035)
levels
significantly
higher,
lymphocyte
.024)
lower
began
COVID-19.Back
symptom
admission.
fatigue,
myalgia.
Lower
higher
levels,
presence
infection,
having
diseases
post-COVID-19
Therapeutic Advances in Gastroenterology,
Год журнала:
2022,
Номер
15, С. 175628482211184 - 175628482211184
Опубликована: Янв. 1, 2022
Prolonged
symptoms
after
COVID-19
are
an
important
concern
due
to
the
large
numbers
affected
by
pandemic.To
ascertain
frequency
of
gastrointestinal
(GI)
manifestations
as
part
long
GI
COVID.A
systematic
review
and
meta-analysis
studies
reporting
in
COVID
was
performed.Electronic
databases
(Medline,
Scopus,
Embase,
Cochrane
Central
Register
Controlled
Trials,
Web
Science)
were
searched
till
21
December
2021
identify
COVID.
We
included
overall
or
individual
excluded
pediatric
those
not
providing
relevant
information.
calculated
pooled
various
all
patients
with
also
using
inverse
variance
approach.
All
analysis
done
R
version
4.1.1
packages
'meta'
'metafor'.A
total
50
included.
The
frequencies
0.12
[95%
confidence
interval
(CI),
0.06-0.22,
I2
=
99%]
0.22
(95%
CI,
0.10-0.41,
97%)
COVID,
respectively.
abdominal
pain,
nausea/vomiting,
loss
appetite,
taste
0.14
0.04-0.38,
96%),
0.06
0.03-0.11,
98%),
0.20
0.08-0.43,
0.17
0.10-0.27,
95%),
respectively,
COVID-19.
diarrhea,
dyspepsia,
irritable
bowel
syndrome
0.10
0.04-0.23,
0.06-0.50,
97%),
0.06-0.37,
respectively.GI
seen
12%
22%
Loss
syndrome,
taste,
pain
five
most
common
Significant
heterogeneity
small
number
for
some
analyses
limitations
review.
Orthopedic Research and Reviews,
Год журнала:
2021,
Номер
Volume 13, С. 141 - 150
Опубликована: Сен. 1, 2021
Abstract:
The
global
pandemic
caused
by
SARS-CoV-2,
or
COVID-19,
continues
to
impact
all
facets
of
daily
life.
Clinical
manifestations
COVID-19
commonly
include
musculoskeletal
symptoms
such
as
myalgias,
arthralgias,
and
neuropathies/myopathies.
inflammatory
response
its
on
the
respiratory
system
have
been
focus
most
studies.
However,
literature
is
more
limited
regarding
implications
for
other
organ
systems,
specifically
system.
Previous
studies
described
how
systemic
inflammation
may
play
a
role
in
bone
joint
pathology.
Furthermore,
it
important
understand
effects
current
therapeutics
used
treatment
In
this
study,
we
will
review
understanding
effect
has
system,
provide
an
overview
patients
infected
with
virus,
address
key
issues
clinicians
during
care
patients.
Keywords:
SARS-CoV-2
European Respiratory Review,
Год журнала:
2022,
Номер
31(166), С. 220071 - 220071
Опубликована: Ноя. 2, 2022
Persistent
breathlessness
>28
days
after
acute
COVID-19
infection
has
been
identified
as
a
highly
debilitating
post-COVID
symptom.
However,
the
prevalence,
risk
factors,
mechanisms
and
treatments
for
remain
poorly
understood.
We
systematically
searched
PubMed
Embase
relevant
studies
published
from
1
January
2020
to
November
2021
(PROSPERO
registration
number:
CRD42021285733)
included
119
eligible
papers.
Random-effects
meta-analysis
of
42
872
patients
with
reported
in
102
papers
found
an
overall
prevalence
26%
(95%
CI
23-29)
when
measuring
presence/absence
symptom,
41%
34-48)
using
Medical
Research
Council
(MRC)/modified
MRC
dyspnoea
scale.
The
pooled
decreased
significantly
1-6
months
7-12
post-infection.
Post-COVID
was
more
common
those
severe/critical
infection,
who
were
hospitalised
females,
less
likely
be
by
Asia
than
Europe
or
North
America.
Multiple
pathophysiological
have
proposed
(including
deconditioning,
restrictive/obstructive
airflow
limitation,
systemic
inflammation,
impaired
mental
health),
but
body
evidence
remains
inconclusive.
Seven
cohort
one
randomised
controlled
trial
suggested
rehabilitation
exercises
may
reduce
breathlessness.
There
is
urgent
need
mechanistic
research
development
interventions
prevention
treatment
Anaesthesia,
Год журнала:
2022,
Номер
77(9), С. 1039 - 1050
Опубликована: Июль 18, 2022
Summary
The
COVID‐19
pandemic
transformed
everyday
life,
but
the
implications
were
most
impactful
for
vulnerable
populations,
including
patients
with
chronic
pain.
Moreover,
persistent
pain
is
increasingly
recognised
as
a
key
manifestation
of
long
COVID.
This
narrative
review
explores
consequences
Publications
identified
related
to
influence
on
burden
pain,
development
new‐onset
because
COVID
proposed
mechanisms
and
vaccines
interventions.
Broadly,
underlying
due
SARS‐CoV‐2
infection
could
be
caused
by
‘systemic
inflammatory‐immune
mechanisms’,
‘direct
neuropathic
mechanisms’
or
‘secondary
viral
treatment’.
Existing
populations
variably
impacted
social
determinants
health
appeared
degree
effect.
increased
absolute
numbers
headache.
In
acute
phase,
headache
presenting
symptom
predicted
milder
course.
New‐onset
was
reportedly
common
likely
involves
multiple
mechanisms;
however,
its
prevalence
decreases
over
time
symptoms
appear
fluctuate.
Patients
requiring
intensive
support
particularly
susceptible
symptoms.
Some
evidence
suggests
steroid
exposure
(often
used
interventions)
may
affect
vaccine
efficacy,
there
no
clinical
repercussions
date.
Although
existing
management
help
symptomatic
relief,
need
advance
research
focusing
mechanism‐based
treatments
within
domain
multidisciplinary
care.
